Patent applications published 15 September 2010
Selected patent applications from the weekly European Patents Bulletin
- Compsn comprising calcium ions and at least one proteolytic enzyme for use in the in vitro and in vivo regeneration of cutaneous and connective tissues
Medevice 2227083*
- Viricidal compsn
Novapharm Research (Australia) 2227084*
- Inhalable compsns having enhanced bioavailability
Cyclotech 2227085*
- Vaginal delivery system
Bayer Schering Pharma 2227220*
- Effervescent tablets and effervescent granules containing carnitine tartrate
Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories 2227221*
- Resuscitation fluid
Simpkins, Cuthbert 2227222*
- Oligo-ethylene glycol-based polymer compsns and methods of use
Medivas; Cornell University 2227223*
- Improved pharmaceutical compsn containing non-ergoline dopamine agonist and method for the preparation thereof
Pharmathen 2227224*
- Coated pharmaceutical or nutraceutical preparation with enhanced pulsed active substance release
Evonik Röhm 2227225*
- Manufacture of tablet
McNeil-PPC 2227226*
- Coating suitable for medicament contact
Valspar Sourcing 2227227*
- Microstructured antimicrobial film
3M Innovative Properties Company 2227228*
- Compsns comprising coenzyme Q-10 and garlic oil for an increased coenzyme Q-10 bioavailability
CPC (Tianjin) Fine Chemicals 2227229*
- Method fro prevention and treatment of reflux injury in the aerodigestive tract and laryngopharynx caused by pepsin
Koufman, Jamie; James, Michael; Josling, Peter 2227230*
- Methods for inhibiting T helper cell differentiation
Fibrogen 2227232*
- IDO inhibitors
Newlink Genetics 2227233*
- Method for inducing hepatocyte proliferation and uses thereof
Can-Fite Biopharma 2227234*
- Mequitazine for treating or preventing pathologies involving histamine H4 receptors
Pierre Fabre Medicament 2227235*
- Methods and compsns for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
University of South Florida 2227236*
- Alginate biomaterials for the treatment of hepatic disorders
Hadasit Medical Research Services & Development; Ben-Gurion University of the Negev Research & Development Authority 2227237*
- Compsns comprising vascular and myocyte progenitor cells and methods of their use
New York Medical College 2227238*
- Probiotic bacteria and regulation of fat storage
Arla Foods 2227239*
- Parvovirus cancer therapy and combination with chemotherapy
DFKZ Deutsches Krebsforschungs-zentrum 2227240*
- Methods of inducing pluripotency involving SOX2 protein
Cytomatrix 2227241*
- Bone morphogenic protein binding peptide
The Regents of the University of California 2227242*
- A pharmaceutical compsn for treating obesity-related disease comprising insulinotropic peptide conjugate
Hanmi Pharmaceutical 2227243*
- CGRP as a therapeutic agent
Mondobiotech Laboratories 2227244*
- Combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of muscle atrophy and related disorders
Novartis 2227245*
- Treatment of fibroses and liver disorders
Apeiron Biologics 2227246*
- Anticancer compsn comprising plant stem cell line derived from Taxus cambrium or procambrium
Unhwa Corp 2227247*
- Adjuvanted glucans
Novartis 2227248*
- Improved immunising compsn
Intervacc 2227249*
- Chlamydia antigens
The President and Fellows of Harvard College 2227250*
- Influenza compsn
GlaxoSmithKline Biologicals 2227251*
- New adjuvant
Ramot at Tel Aviv University 2227252*
- Vaccine comprising monocyte or immature myeloid cells (IMC) which were loaded with the ligand of natural killer T cell and antigen
Seoul National University Industry Foundation 2227253*
- Combined treatment with an EGFR kinase inhibitor and an inhibitor of C-kit
OSI Pharmaceuticals 2227254*
- Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
The Rockefeller University 2227255*
- Method for treating bone fracture with anti-sclerostin antibodies
Amgen 2227256*
- Methods and devices for minimally-invasive extraocular delivery of radiation to the posterior portion of the eye
Salutaris 2227257*
- Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
Bristol-Myers Squibb 2227296*